Scientists have reported another breakthrough in the development of vaccines against cancer. Injections under immunotherapy successfully reduced tumors in 54% of patients.
Only that the Swedish Nobel Committee awarded the prize in physiology or medicine to two scientists for their work in the field of immunotherapy. This trend in Oncology is the most promising, as indicated by the results of the newly published study. Clinical trials of vaccines for the treatment of aggressive forms of several types of cancer have been successful. We are talking about the fight against ovarian tumors, colon, prostate and esophagus. But these types of cancer is not limited. Approximately 25% of victims of breast cancer mutations of the HER2 gene cause a more aggressive tumor growth and a marked increase in the risk of relapse even after remission.
Researchers from the National institutes of health have developed a new immunotherapy that has not yet been tested in patients with breast cancer, But it has the potential to resist the fatal gene. Currently, the vaccine stopped the growth in 54% of tumors caused by HER2 gene in a small clinical study. And one woman the vaccine is completely freed from ovarian cancer for 18 months. The results of this study can be considered a real breakthrough in the further development of immunotherapy.
Magicforum recalls that at the time of introduction of chemotherapy, this technique was considered the most significant achievement in Oncology, since it has radically changed the rules of the game in the fight against tumors. Unfortunately, not all malignant tumors respond to this treatment. The differences in this reaction, patients often have written in their genes. Therefore, in patients with breast cancer test the ability of a mutation of the HER2 gene. Normally, this gene regulates the growth of cells of breast tissue. But his mutations break their functionality, leading to aggressive development of tumors very difficult to treat. (READ MORE)